Program

 

Day 1: Friday, November 8, 2019
12:30-13:00Lunch
13:00-13:15Welcome

13:15-15:30

 

 

 

 

 

 

 

 

 

Plenary Session 1: Infection & Cancer Overview

Infectious causes of cancer: many opportunities for intervention

Doug Lowy, National Cancer Institute, Bethesda, USA

 

Title TBA 

Yuan Chang, University of Pittsburgh, Pittsburgh, USA

 

Title TBA 

Tak W. Mak, Princess Margaret Cancer Centre, University of Toronto, Canada and The University of Hong Kong, Hong Kong,China

15:30-16:00Break

16:00-18:30

 

 

 

 

 

Plenary Session 2: Experimental Models 
Leveraging orthotopic models of colon cancer to uncover disease mechanisms
Ömer H. Yilmaz, MIT Koch Institute for Integrated Cancer Research, Cambridge, USA

 

Title TBA
Xin Lu, University of Oxford, Oxford, UK

18:30-20:30Opening Reception & Poster Session A

 

Day 2: Saturday, November 9, 2019

8:30-10:30

 

 

 

 

 

 

 

 

 

Plenary Session 3: Prevention, Early Detection & Screening

Title TBA
Julia Brotherton, VCS Foundation, East Melbourne, Victoria, Australia

 

Screening for nasopharyngeal carcinoma using circulating EBV DNA
Dennis Lo, The Chinese University of Hong Kong, Hong Kong,China

 

Prevention of gastric cancer in H. pylori infected patients: Insights from population-based study
Wai Keung Leung, The University of Hong Kong, Hong Kong,China

10:30-11:00Break

11:00-13:00

 

 

 

 

 

 

 

 

 

 

 

Plenary Session 4: Molecular Pathology, Genetics
Title TBA
SY Leung, The University of Hong Kong, Hong Kong,China


Molecular pathology, genetics and genomics of HCC
Irene Ng, The University of Hong Kong, Hong Kong,China


Title TBA
Maura L. Gillison, The University of Texas MD Anderson Cancer Center, Houston, USA


Title TBA
KW Lo, Chinese University of Hong Kong, Hong Kong,China

13:00-14:30Poster Session B/Lunch

14:30-16:30

 

 

 

 

 

 

 

 

Plenary Session 5: Molecular Pathology, Epigenetics & Epidemiology
Epstein-Barr virus is an epigenetic driver of gastric cancer
Atsushi Kaneda, Chiba University, Japan


Epigenetic pathway of infection-induced cancer
Toshikazu Ushijima, National Cancer Center, Japan


Title TBA
Patrick Moore, University of Pittsburgh, Pittsburgh, PA, USA

16:30-16:45Break

16:45-18:30

 

 

 

 

 

 

 

 

 

Plenary Session 6: Molecular Pathology, Immunological Impact
Title TBA
Graham Taylor, Cancer Research UK Birmingham Centre, Birmingham,United Kingdom


Immune microenvironment of hepatitis B virus-related hepatocellular carcinoma
Valerie Chew, Translational Immunology Institute (TII), SingHealth-DukeNUS, Singapore


New Molecular Targets for Intervention in H. pylori-induced Gastric Inflammation and Carcinogenesis
Keith Wilson, Vanderbilt University Medical Center, Nashville, TN, USA

 

Day 3: Sunday, November 10, 2019

8:30-10:30

 

 

 

 

 

 

 

 

Plenary Session 7: Emerging Therapeutics I
Title TBA
Andrew Zhu, Massachusetts General Hospital, Boston, USA


Title TBA
Anthony Chan, Chinese University of Hong Kong, Hong Kong,China


Title TBA
Cornelis J.M. Melief, Leiden Univ. Medical Center & ISA Pharmaceuticals BV, Leiden, Netherlands

10:30-11:00Break

11:00-12:30

 

 

 

 

 

 

 

 

Plenary Session 8: Emerging Therapeutics II
T cell therapies targeting EBV and HPV positive malignancies
Helen Heslop, Baylor College of Medicine, USA


Immunotherapies for cancers attributable to infectious pathogens: Lessons learned from HPV
Cornelia Liu Trimble, The Johns Hopkins University School of Medicine, Baltimore, MD, USA


Title TBA
Cassian Yee, UT MD Anderson Cancer Center, Houston, TX, USA

12:30-13:30

 

 

Closing Keynote
Plasmidoses: Diseases linked to a novel class of human pathogens in common human cancers
Harald zur Hausen, German Cancer Research Center, Heidelberg, Germany
13:30Departure